Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + Fludarabine + Cyclophosphamide in Relapsed Follicular Lymphoma
NCT00393107Phase 2Completed
- Sponsor
- Gruppo Italiano Studio Linfomi
- Start
- Mar 2000
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2 trial of rituximab in follicular lymphoma (FL), sponsored by Gruppo Italiano Studio Linfomi. Primary endpoints: Toxicity during the treatment period and Objective Response Rate. Started Mar 2000; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00393107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00393107.